Mounjaro Denied? How to Appeal Your Insurance Denial (2026)

Mounjaro (tirzepatide) is the first dual GIP and GLP-1 receptor agonist approved for Type 2 diabetes, with clinical data showing superior glucose control and weight reduction compared to existing GLP-1 therapies. Despite this, insurance Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization denials are common. This guide explains exactly how to appeal.

Mounjaro vs. Zepbound: Getting the Right Drug Prescribed

Before appealing, confirm your physician's prescription matches the intended indication:

If your plan covers diabetes medications but excludes AOMs, your appeal will be different depending on which product was prescribed and for which indication.

Why Insurers Deny Mounjaro

Step Therapy Within the Diabetes Drug Class

Most PBMs (pharmacy benefit managers) require progression through diabetes drug classes:

1. Metformin — required by virtually all plans
2. Sulfonylureas or DPP-4 inhibitors — commonly required as second-line
3. GLP-1 receptor agonist (Trulicity, Ozempic, Victoza) — often required before a dual agonist
4. Mounjaro — approved once prior agents failed

If you haven't been on a GLP-1 previously, the insurer may require you to try one first. Your appeal strategy depends on whether you've tried these agents and the results.

Preferred Agent Available

Many formularies list Trulicity (dulaglutide) or Ozempic (semaglutide) as preferred GLP-1 agents. To approve Mounjaro, the insurer may require documentation of inadequate response to a preferred agent.

Key appeal argument: Mounjaro (tirzepatide) adds GIP receptor agonism to GLP-1 agonism. The SURPASS-2 trial showed tirzepatide reduced HbA1c by 0.5–0.7% more than semaglutide, with significantly greater weight reduction. If HbA1c remains above target on a GLP-1 alone, this is your medical necessity argument for the incremental benefit of dual agonism.

Prior Authorization Incomplete

Many PA denials are administrative — the request was missing HbA1c values, current medication list, or the treating physician's NPI. A corrected PA often resolves these.

SURPASS Trial Evidence for Appeals

The SURPASS clinical development program provides robust evidence for Mounjaro's clinical superiority:

• SURPASS-2: Tirzepatide 10mg reduced HbA1c by 2.01% vs. semaglutide 1mg's 1.86% reduction. Weight reduction was 7.8–11.2kg vs. 5.9kg with semaglutide.
• SURPASS-3: Tirzepatide significantly outperformed insulin degludec on both glycemic control and weight.
• SURPASS-4: In patients with high CV risk, tirzepatide achieved superior HbA1c and weight outcomes vs. glargine.

These head-to-head comparisons are powerful appeal evidence when the insurer's step therapy requires trying Ozempic or another GLP-1 first — you can argue that after failing to achieve HbA1c target on a GLP-1, Mounjaro's additional mechanism provides clinically meaningful incremental benefit.

Building Your Mounjaro Appeal

Documentation Required

1. HbA1c values — current and historical, showing inadequate glycemic control
2. Current medication list with doses and start dates
3. Documentation of prior agents tried — with dates, doses, duration, and reason for change (inadequate control, side effects, intolerance)
4. Physician letter explaining:
   • Current diagnosis and glycemic control status
   • Why existing agents were insufficient
   • Why Mounjaro's dual GIP/GLP-1 mechanism provides clinical benefit over single-mechanism GLP-1s
   • Reference to SURPASS-2 superiority data if applicable
5. Insurance criteria — request the plan's specific PA criteria for tirzepatide and address each point

Step Therapy Exception Arguments

If the plan requires trying a GLP-1 first and you have a reason to skip that step:

• Contraindication: History of thyroid C-cell tumors (applies to all GLP-1s), pancreatitis, severe GI issues with prior GLP-1 experience
• Prior failure on a GLP-1: Document the specific agent, dose, duration, and result
• Comorbid obesity requiring superior weight effect: If obesity-related comorbidities make Mounjaro's greater weight reduction clinically important, document this explicitly

External Independent Review: Complete Guide" class="auto-link">External Review

If internal appeal fails, request external review within 60 days. External reviewers — typically endocrinologists or internal medicine specialists — are familiar with the SURPASS data and may view tirzepatide favorably relative to insulin alternatives.

Get Your Mounjaro Appeal Letter

ClaimBack generates a professional tirzepatide appeal letter citing the SURPASS trial data, your insurer's specific step therapy criteria, and the clinical arguments for Mounjaro over preferred alternatives.

Start your Mounjaro appeal at ClaimBack →

Related Reading:

• Ozempic Denied by Insurance?
• Wegovy Denied by Insurance?
• GLP-1 Insurance Coverage Complete Guide
• Prior Authorization Denied: How to Appeal